July 02 2024 12:03:54 — Fresenius Kabi launches subcutaneous Tyenne® (tocilizumab-aazg) in the U.S., enhancing affordable chronic autoimmune disease treatments and advancing its (Bio)Pharma momentum.
Tyenne is the company’s third biosimilar in the U.S., previously launched in an intravenous form.